Eculizumab‐related drug reaction in a patient with neuromyelitis optica

Eculizumab is approved for treatment of antibody positive neuromyelitis optica, myasthenia gravis, and hematologic disorders like paroxysmal nocturnal hemoglobinuria. Drug rash has not yet been reported as a side effect of eculizumab. We report a case of a cutaneous drug reaction soon after introduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Rishi, Romo, Moises, Nelson, Flavia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909165/
https://www.ncbi.nlm.nih.gov/pubmed/36789316
http://dx.doi.org/10.1002/ccr3.6835
_version_ 1784884511494897664
author Sharma, Rishi
Romo, Moises
Nelson, Flavia
author_facet Sharma, Rishi
Romo, Moises
Nelson, Flavia
author_sort Sharma, Rishi
collection PubMed
description Eculizumab is approved for treatment of antibody positive neuromyelitis optica, myasthenia gravis, and hematologic disorders like paroxysmal nocturnal hemoglobinuria. Drug rash has not yet been reported as a side effect of eculizumab. We report a case of a cutaneous drug reaction soon after introduction of eculizumab therapy in a patient with refractory neuromyelitis optica. Clinicians should be aware of a drug reaction as a possible adverse reaction to eculizumab.
format Online
Article
Text
id pubmed-9909165
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99091652023-02-13 Eculizumab‐related drug reaction in a patient with neuromyelitis optica Sharma, Rishi Romo, Moises Nelson, Flavia Clin Case Rep Case Report Eculizumab is approved for treatment of antibody positive neuromyelitis optica, myasthenia gravis, and hematologic disorders like paroxysmal nocturnal hemoglobinuria. Drug rash has not yet been reported as a side effect of eculizumab. We report a case of a cutaneous drug reaction soon after introduction of eculizumab therapy in a patient with refractory neuromyelitis optica. Clinicians should be aware of a drug reaction as a possible adverse reaction to eculizumab. John Wiley and Sons Inc. 2023-02-08 /pmc/articles/PMC9909165/ /pubmed/36789316 http://dx.doi.org/10.1002/ccr3.6835 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Sharma, Rishi
Romo, Moises
Nelson, Flavia
Eculizumab‐related drug reaction in a patient with neuromyelitis optica
title Eculizumab‐related drug reaction in a patient with neuromyelitis optica
title_full Eculizumab‐related drug reaction in a patient with neuromyelitis optica
title_fullStr Eculizumab‐related drug reaction in a patient with neuromyelitis optica
title_full_unstemmed Eculizumab‐related drug reaction in a patient with neuromyelitis optica
title_short Eculizumab‐related drug reaction in a patient with neuromyelitis optica
title_sort eculizumab‐related drug reaction in a patient with neuromyelitis optica
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909165/
https://www.ncbi.nlm.nih.gov/pubmed/36789316
http://dx.doi.org/10.1002/ccr3.6835
work_keys_str_mv AT sharmarishi eculizumabrelateddrugreactioninapatientwithneuromyelitisoptica
AT romomoises eculizumabrelateddrugreactioninapatientwithneuromyelitisoptica
AT nelsonflavia eculizumabrelateddrugreactioninapatientwithneuromyelitisoptica

Ejemplares similares